|
Effect of ercc1, xrcc1 and gstp1 polymorphisms on clinical response and adverse events of platinum-based chemotherapy in epithelial ovarian cancer patients |
|---|---|
| รหัสดีโอไอ | |
| Title | Effect of ercc1, xrcc1 and gstp1 polymorphisms on clinical response and adverse events of platinum-based chemotherapy in epithelial ovarian cancer patients |
| Creator | Salisa Liblab |
| Contributor | Nutthada Areepium, Apichai Vasuratna |
| Publisher | Chulalongkorn University |
| Publication Year | 2561 |
| Keyword | Ovaries -- Cancer -- Patients, Cancer -- Chemotherapy, รังไข่ -- มะเร็ง -- ผู้ป่วย, มะเร็ง -- เคมีบำบัด |
| Abstract | Platinum-based chemotherapy is the first line chemotherapy regimen for epithelial ovarian cancer (EOC). Pharmacogenomics is one factor that might affect its efficacy and toxicity. This cohort study was aimed to investigate the association between ERCC1, XRCC1 and GSTP1 polymorphisms on clinical responses and adverse events related to platinum-based chemotherapy in Thai EOC patients. Fifty-two patients with advanced EOC were enrolled in this cohort study. The mean age was 55.7 years old. Genotyping analysis of ERCC1 (C>A, rs3212986), XRCC1 (A>G, rs25487) and GSTP (A>G, rs1695) were performed which allele frequencies were found at 35.6%, 28.9% and 10.6%, respectively. Neither of them associated with clinical responses. However, patients with homozygous variant type (A/A) of ERCC1 C8092A had higher risk of platinum-resistance (75% vs 16.7%, P = 0.046). In addition, the significant association of GSTP1 polymorphism and grade 2 anemia was found. Patients with A/G genotype of GSTP1 had higher rate of grade 2 anemia than those with wild type (81.8% vs 46.3%, P = 0.036). Genetic polymorphisms of ERCC1 and GSTP1 might be advantageous biomarkers to predicting clinical response and toxicity of platinum-based chemotherapy in Thai EOC patients. |
| URL Website | cuir.car.chula.ac.th |
